PBAC advice on equitable access to GLP-1 obesity treatments

Page last updated: 17 March 2026

On 6 March 2025, Minister Butler wrote to the Pharmaceutical Benefits Advisory Committee (PBAC) to request the Committee’s advice on equitable access to glucagon-like peptide-1 receptor agonist (GLP-1) obesity treatments through the Pharmaceutical Benefits Scheme (PBS). The PBAC provided advice on this matter at its November 2025 meeting.

The PBAC welcomed and considered input from individuals who have used GLP-1s, other individuals, health care professionals and organisations.

The PBAC Minutes and a summary of consumer inputs for this item are now available on the ‘PBAC advice on equitable access to GLP-1 obesity treatments’ web page.